01.06.2013 Views

tıklayınız - Türk Pediatrik Kardiyoloji ve Kalp Cerrahisi Derneği

tıklayınız - Türk Pediatrik Kardiyoloji ve Kalp Cerrahisi Derneği

tıklayınız - Türk Pediatrik Kardiyoloji ve Kalp Cerrahisi Derneği

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

MECHANICAL CIRCULATORY SUPPORT IN PEDIATRIC PATIENTS<br />

HAKAN AKINTÜRK<br />

JUSTUS LIEBIG UNIVERSITY, GERMANY<br />

Introduction<br />

End stage cardiac failure in children is a frustrating diagnosis. Mechanical circulatory<br />

support (VAD) is sometimes the only possible treatment either to bridge for<br />

transplantation or to stabilize the circulatory situation in order to treat a transient<br />

cardiac failure.<br />

Methods<br />

Between 1997 and 2011 we treated 27 patients (29 applications) in end stage cardiac<br />

failure with different extracorporeal VAD Systems. From 1997 to 2001 we implanted<br />

the Medos Excor (group A) in 11 patients (LVAD n=5, RVAD n=2.BiVAD n=4), median<br />

age 2y (r: 20d-11y). Diagnosis of group A consisted of: DCM n=4, myocarditis n=2;<br />

postcardiotomy n=2, post HTX n=2. From 2006 to 2011, the Berlin Heart System (group<br />

B), 17 pts (19 applications) (LVAD n=7, BiVAD n=12), median age 8y (r: 95d-19y). In<br />

group B patients suffered from DCM/RCM n=14; chronic myocarditis n=2; ischemic<br />

cardiomypathy n=1. Application of VAD in group A was electi<strong>ve</strong> in 7 pts., urgent in 4<br />

pts., in group B electi<strong>ve</strong> in 9, urgent in 10 procedures. ECMO was performed only in<br />

group B in 11 patients as a bridge to VAD.<br />

Results<br />

In group A 5 pts. (45%) survi<strong>ve</strong>d, 3 bridged to HTX, 2 reco<strong>ve</strong>red. Median VAD therapy<br />

was 9 d (r.: 0,5-30d). 6 pts. died (ARDS n=2, brain death n=2, sepsis n=1, bleeding n=1).<br />

In group B 12 pts. (66%) survi<strong>ve</strong>d, 7 bridged to HTX, 4 to reco<strong>ve</strong>ry. Median VAD time<br />

was 30d (r:8-283d). 6 pts. (33%) died (sepsis n=4, brain death n=2). Increased risk of<br />

mortality was associated with pre-VAD cerebral insult (odds-ratio: 12,8, infection on<br />

VAD (odds-ratio: 5,3) and surgical revision on VAD (odds-ratio:4,2).<br />

Conclusion<br />

In end stage cardiac failure VAD therapy in pediatric patients is successful as a bridge<br />

to transplant or to reco<strong>ve</strong>ry. Serious complications are always possible, so that VADtherapy<br />

should be postponed as long as possible. Reducing infections and bleeding<br />

during VAD therapy is a mayor step to an impro<strong>ve</strong>d outcome.<br />

57

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!